Prognostic implication of heterogeneity and trajectory progression induced by enzalutamide in prostate cancer

Overview of attention for article published in Frontiers in endocrinology, March 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 1 Dimensions

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 11,872 followers.

RT @glycolukasz: Another unexpected #glycotime instance: human #MANEA #GH99 #endomannosidase is one of the genes whose upregulation by enza…

18 May 2023

Reply Repost Favourite

RT @glycolukasz: Another unexpected #glycotime instance: human #MANEA #GH99 #endomannosidase is one of the genes whose upregulation by enza…

18 May 2023

Reply Repost Favourite

Another unexpected #glycotime instance: human #MANEA #GH99 #endomannosidase is one of the genes whose upregulation by enzalutamide (an androgen receptor antagonist) treatment is associated with relapse-free survival of prostate cancer. https://t.co/wQa2sbX

18 May 2023

Reply Repost Favourite

New Research: Prognostic implication of heterogeneity and trajectory progression induced by enzalutamide in prostate cancer: Background Enzalutamide, as a second-generation endocrine therapy drug for prostate cancer (PCa), is… https://t.co/IVsPeF6ZRA #End

16 Mar 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.